Nelum Pharma

Nelum Pharma is a clinical-stage biotechnology company focused on developing innovative therapies for pancreatic cancer and other solid tumors. The company's lead candidate, NLM-001, is a small molecule Hedgehog pathway inhibitor designed to modulate the tumor microenvironment and improve the delivery of chemotherapy. By targeting the dense stroma associated with pancreatic ductal adenocarcinoma, Nelum aims to enhance the efficacy of standard-of-care treatments. The company is currently advancing NLM-001 through Phase 2 clinical trials to address the significant unmet medical need in oncology. Nelum's strategy emphasizes the optimization of existing biological pathways to create safer and more effective treatment regimens for patients with hard-to-treat cancers.